Endologix, Inc. (NASDAQ:ELGX)

CAPS Rating: 2 out of 5

The Company develops, manufactures, sells and markets minimally invasive therapies for the treatment of cardiovascular disease.


Player Avatar nibs61 (< 20) Submitted: 12/17/2009 6:51:27 AM : Outperform Start Price: $4.80 ELGX Score: +169.02

Bought this one in my personal portfolio. Endologix, Inc. is a developer of vascular disease treatments, specifically abdominal aortic aneurysms.
The company’s primary product is a next-generation
endoluminal stent graft, a minimally invasive device used to help the 1.7 million Americans with weakened aortas. The Baby Boomers will need plenty of treatments to live to their life expectancy and the growth potential of this company is outstanding.

Featured Broker Partners